Skip to main content
Brian Van Tine, MD, Oncology, Saint Louis, MO, Barnes-Jewish Hospital

BrianAndrewVan TineMD

Oncology Saint Louis, MO

Hematologic Oncology, Sarcoma

Instructor, Internal Medicine, Washington University School of Medicine

Dr. Van Tine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Van Tine's full profile

Already have an account?

Summary

  • I have set out on a lifelong mission to make an impact in the treatment of patients with sarcoma. I spent the first three years of my career developing a very large and robust trials-based sarcoma program at Washington University in St. Louis. This is now the largest program in the Midwest, and I have been the PI of over 40 clinical trials. I was awarded an early career development grant by the Sarcoma Alliance through Research and Collaboration.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
  • University of Alabama School of Medicine
    University of Alabama School of MedicineClass of 2005

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • MO State Medical License
    MO State Medical License 2007 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 p... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
  • A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Emerging Agents: Metabolism, DNA Repair, and Hypoxia 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Committees

  • Member, NRG Sarcoma Committee 2014 - Present

Research History

  • Sarcoma Alliance for Research2012 - 2015

Professional Memberships

Hospital Affiliations